The psychotropic effectso fPsilocybe "magic" mushroomsa re caused by the l-tryptophan-derived alkaloid psilocybin.D espite their significance,t he secondary metabolome of these fungi is poorly understood in general. Our analysis of four Psilocybe speciesi dentified harmane, harmine, and ar ange of other l-tryptophan-derived b-carbolines as their natural products,w hichw as confirmed by 1D and 2D NMR spectroscopy.S table-isotope labeling with 13 C 11 -l-tryptophan verifiedt he b-carbolines as biosynthetic products of these fungi. In addition, MALDI-MS imaging showedt hat b-carbolines accumulate toward the hyphal apices.A sp otent inhibitors of monoamine oxidases, b-carbolines are neuroactive compounds and interfere with psilocybin degradation. Therefore, our findings represent an unprecedented scenario of natural product pathways that diverge from the same buildingb lock and produce dissimilar compounds, yet contribute directlyo ri ndirectly to the same pharmacological effects.
Introduction
Since ancient times, vision-inducing, consciousness-altering natural products, so-called entheogens, have been used for spiritualp urposes.T he producing plants or fungi have accompanied humankind and impactedthe genesis of culture and religion. [1] Indisputably,m ushrooms producing psilocybin (1, Scheme 1) rank among the most prominente ntheogens and were considered the "flesh of the gods" (teonanacatl) by the Aztecs. [1] Numerous species within the fungal genus Psilocybe and other genera biosynthesize 1 which represents the phos-phorylated prodrug to the psychotropic agent psilocin (2), [2] first described by Albert Hofmanna nd co-workers sixty years ago. [3] Subsequently,N -methylated l-tryptophan as well as indoleethylamines,i .e.,t he intermediates of 1 baeocystin, nor-Scheme1.Schematicoverviewo np sychoactiveprinciples of Psilocybe mushrooms( green) and ayahuasca (blue), their biosynthetic origin, and their inactivation in the human body by monoamine oxidase(MAO) A. baeocystin, and norpsilocin were discovered. [4] Compound 2 interferes with serotonergic neurotransmission because it acts as ap artial agonistp rimarily on the 5-hydroxytryptamine( 5-HT) 2A -receptor. [5] The perceptual and somatic effects include synesthesia, visual hallucinations, dilated pupils,a nd others. [6] The effects last fors everalh ours before they subside when 2 is eliminated both renally through O-glucuronylation and by formation of 4-hydroxyindol-3-yl-acetaldehyde (Scheme 1). The latter process is catalyzed by the monoamine oxidase isozyme A( MAO A), [7] am itochondrial flavin-dependent enzyme that oxidatively deaminates serotonina nd other biogenic and neuroactive amines.C onsequently,M AO inhibitors generally increase the pharmacological effects of such bioactivea mines.
Anothere ntheogen that has traditionally been consumedi n spirituala nd healing ceremonies is ap sychotropic brew, known by its vernacular name ayahuasca, aQ uechua term literally meaning "vine of the souls". Unlike Psilocybe mushrooms, it is not the product of as ingle biological species. Rather,a yahuasca consists of leaves of N,N-dimethyltryptamine (DMT, 3, Scheme 1) producers, e.g., Psychotria viridis (Rubiaceae, coffee family). [9] Compound 3 is inactive when taken up orally,but becomes neuroactive in the presence of MAO Ai nhibitors that prevent 3 degradation in the human gut (Scheme 1). Such inhibitors are present in ayahuasca as well, because its second ingredient is the bark of the jungle vine Banisteriopsis caapi (Malpighiaceae), which produces b-carbolines, which are strong reversible MAO inhibitors. [8] Ayahuasca's synergism, caused by two separate species, has empirically been discovered in pre-Columbian times by South American natives. [9] It compensates the fact that synchronous production of ab ioactive compound and the inhibitor of its own degradationa se nhancer in one single speciesisu nprecedented for psychotropic natural products.
Besides 1 and its congeners, other amino-acid derived natural productsh ave not been reported yet from Psilocybe mushrooms. Therefore, their secondary metabolomes appear surprisingly little understood, despite 60 years of intensive research. We addressed this knowledge gap and describe here an in-depth re-analysis of natural-product profiles of five Psilocybe species. In all of them, we identified b-carbolines as their products,i .e.,ametabolicp rofile reminiscent of the active principles of ayahuasca.
Results and Discussion
In the course of metabolic profiling of carpophores of Psilocybe mexicana,w eroutinelye xtracted with methanol, using ap ublished protocol, [4c] and analyzed the crude extracts by LC-HR-ESI-MS. As expected, 1,i ts immediate biosynthetic precursors baeocystin and norbaeocystin, and low amounts of its dephosphorylated follow-up compound 2 were detected. However, we also identified two very minor mass spectrometric signals that showed retention times and masses dissimilar to those of authentic standards of 1 and its precursors (Figure1A). These signals appeared at t R = 4.53 min (m/z = 183.0916[ M+ +H] + + )a nd at t R = 4.89 min (m/z = 213.1022[ M+ +H] + + ). We hypothesized that b-carbolines may account for these signals as the ob-served masses are in good agreement with that of harmane (4, Figure 1 ) and harmine (5) . [10] Upon exposure to UV light, b-carbolines fluoresce. [11] Therefore, we repeated the analysis, this time using an acidic aqueous mushroom extract and an HPLC instrumenti nterfaced to af luorescenced etector,e xcitation was at l = 340 nm, emissionw as recorded at l = 410 nm. The signals were detected again, and authentic 4 and 5 standards showedi dentical retention times and masses ( Figure 1B) .
We analyzed acidic aqueous extracts of other Psilocybe species by HPLC and fluorescenced etection ( Figure 1C )t oi nvestigate if b-carbolines were present in those fungi as well. Compound 4 and, in lower quantities, 5 were found (t R = 2.98 and 3.16 min) in carpophores of P. cyanescens, P. semilanceata,a nd of two P. cubensis isolates,a sw ella si nP. mexicana (both sclerotia and mycelium), and in P. cubensis mycelium. In addition to the above-mentioned b-carbolines, we detected norharmane (6, t R = 2.85 min, Figure 1 ) and perlolyrine (7, t R = 3.49 min), and identified them by their masses (m/z = 169.0763 and 265.0974[ M+ +H] + + )a nd by comparison with synthetic standards. The latter compound is knowna saplant alkaloid from Codonopsis pilosula (Campanulaceae, bellflowerf amily). [12] Overall,t he b-carboline pattern was quantitatively and qualitatively inhomogeneous amongs pecies, yet indicated that their occurrence is i) more widespread within the genus Psilocybe and ii)independent of the developmental stage. For final evidence that Psilocybe fungi contain b-carbolines, we purified the two major compounds from P. cubensis carpophores. Subsequent 1D and 2D NMR spectroscopy resulted in spectra (Figures S1-S10, Table S1, Supporting Information) that were identical to reported data for 4 and 5. [13] Biosynthetically, b-carbolines derive from tryptamine and have been isolated from plants, bacteria, and various fungi including basidiomycetes. [10, 14] To confirmt hat the compounds are intrinsic Psilocybe products,w ecarriedo ut stable-isotope labeling with 13 C 11 -l-tryptophan and P. mexicana mycelium in liquid axenic culture under controlled laboratory conditions, along with an unlabeled control,a nd detected 4, 6,a nd 7 again. In the stable-isotope-treated cultures,t he masses of the carbolines expectedly increased by ten mass units ( Figure 2 ). This is compatible with the incorporationo ft en 13 Ca toms, i.e., a 13 C 10 -tryptamine moiety.T hus, we had excludedacarboline sourceo ther than Psilocybe's intrinsic cellular metabolism.
We detected two further compounds in minor quantities. The first one whosem ass was identical to that of harmol( 8, m/z = 199.0869[ M+ +H] + + )w as eluted at t R = 4.26 min. However, authentic 8 showed an shorter retention time (t R = 3.99 min, Figure 2 ), which points to an isomer of 8 as Psilocybe metabolite. P. mexicana mycelium also contained ac ompound at t R = 4.89 min (m/z = 213.1025 [M+ +H] + + ). Even thought his molecular mass is identicalt ot hat of 5,t he retention time was not, as this unidentified compound virtually co-eluted with 4 at t R = 4.53 min.
This mass is consistentw ith that of cordysinins Ca nd D( 9 and 10), i.e.,e nantiomeric b-carbolines described from the caterpillar fungus Ophiocordyceps sinensis. [15] Comparison with a synthesized mixture of 9 and 10 confirmed that one of those compounds, or both, is a P. mexicana metabolite as well.
P. cubensis FSU12410 mycelia and carpophores were used to quantify the concentrationo f4,i .e.,t he major b-carboline in the fungal biomass ( Figure 1C ,T able S2, Supporting Information). Although mycelia showed ac oncentration of 21 mgg À1 dried biomass,w efound a1 00-fold lower concentration in the carpophores (0.2 mgg À1 ). Sclerotia of P. mexicana contained 1.4 mgg À1 4 and 1.6 mgg À1 5.N ext, we used MALDI imaging to investigate the spatial distribution of 4 in fungal mycelium. An actively growing P. cubensis culture wass creened for ac ompound with m/z 183.1(AE 0.7) Da, which corresponds to 4 ( Figure 3 ). The signals of maximum intensity localized to the hyphal tips while more maturea reas showed low abundance.
Considered divine by native CentralA mericans, Psilocybe mushrooms produce 1,an atural product that has been used both as recreational drug and an immensely valuablec andidate pharmaceutical, currently in advanced clinical trials, to treat anxiety and depression. [16] Despite their history and importance, the mushrooms' capacity to make further compounds hasr eceived deceptively little attention. We identified five Psilocybe species as b-carboline producers. This capacity of 1-producing mushrooms is remarkablei nt he light of the synergistic pharmacology. 4 and 5 are potent reversible inhibitors of mammalian brain and liver MAO A( K i = 8.9 and 0.5 nm,f or brain, K i = 9.9 and 0.2 nm for liver). [17] Human placental MAO A is inhibited at K i = 7.2 mm. [18] Furthermore, tetrahydro-b-carbolines do not inhibit MAO A, yet represent neuroactive natural products as well as they moderately inhibits erotonin reuptake. [19] Conclusions Psilocybe mushrooms produce an ayahuasca-like andp otentially similarly synergistic set of metabolites that may impact upon onset and duration of their effects. Remarkably, both pathways originate from the same generic building block, ltryptophan, yet take different routes leading to dissimilar compoundsw hose bioactivities in return contributedirectly and indirectly to the same pharmacology (Scheme 1). This is a uniquec ase in fungal chemistry and distantly related to the bacterium Streptomycesc lavuligerus that synchronously produces both the b-lactam antibiotic cephamycin and the b-lactamaseinhibitor clavulanic acid. [20] Despite the co-occurrence of 1 and MAO inhibitors in Psilocybe,n umerous studies with pure synthetic compound have shownt hat the somatic, endocrinic,a nd psychotropic effects are the sole consequence of 1 uptake. [21] Future pharmacologi- cal research is therefore warranted to determine to what extent Psilocybe b-carbolines contributet ot he actual psychotropic effects of magic mushrooms. Compounds 1 and 2 are hypothesized to fulfill a protectivef unction in the mushrooms by altering the behavior of invertebratep redators. [22] Our results therefore also relate to chemical ecology and may help understand if indoleethylaminesa nd b-carbolines co-evolved to fulfill and enhance the same biological functiont hrough addressing dissimilar targets.
Experimental Section
Materials and microbiological methods Chemicals, solvents, and media components were purchased from Cambridge Isotope Laboratories, Deutero, Sigma-Aldrich, Roth, and VWR. Reference compounds of 4 and 5 were purchased from Sigma. Compounds 1, 2,b aeocystin, and norbaeocystin were purified from P. cubensis carpophores. [4c, d] Reference compounds of 6-10 were synthesized (below). Psilocybe isolates (Table S3 , Supporting Information) were maintained on malt extract/peptone (MEP) solid medium (30 gL À1 malt extract, 3gL À1 soy peptone, 18 gL À1 agar,p H5.6) at t = 23 8Ci nt he dark. P. mexicana sclerotia were produced in preserving jars filled with rye, supplemented with cow manure and straw,a nd kept in the dark for 3months. Carpophore production with P. cubensis and P. mexicana was carried out as described. [4c] Carpophores of P. cyanescens and P. semilanceata were collected near Jena, Germany,a nd dikaryotic isolates thereof deposited in the Jena Microbial Resource Collection (Table S3 ).
Stable-isotope labeling P. mexicana FSU13617 was grown in 50 mL liquid MEP medium amended with 1mm 13 C 11 -l-tryptophan (or 1mm unlabeled l-tryptophan for control), for 14 d. The biomass was harvested by filtration, lyophilized, homogenized and extracted with 20 %( v/v)a cetic acid in water.A fter filtration, the liquid was evaporated under reduced pressure, and the residue was solved in MeOH, filtered, and used for LC/MS (below).
Naturalproductextraction
Initially,m ycelia and carpophores were lyophilized, ground, and extracted with anhydrous MeOH, as described to extract 1 gently and to minimize its artificial dephosphorylation to 2.
[4c] For improved carboline yields, the fungal biomasses (mycelia, carpophores, or sclerotia) were lyophilized, pulverized, and the powder solved in 0.1 m HCl and subsequently extracted with methylene chloride (1:1, v/v). The aqueous phases were collected, the pH value adjusted to 12 using NaOH, which was followed by extractions with methylene chloride. The organic phases were dried under reduced pressure in ar otary evaporator.T he resulting crude extracts were dissolved in methanol, centrifuged and filtered, and subsequently used for chromatographic analysis or purification. To quantify 4 titers in fungal biomass, the areas under the curve (AUCs) in the extracted ion chromatograms were determined and referenced to astandard curve recorded with authentic 4.
Chromatographic purification of 4a nd 5
Preparative HPLC was performed using an Agilent 1260 instrument equipped with Phenomenex Luna C 18 column (250 21.2 mm, 10 mmp article size), and run with 0.1 %t rifluoroacetic acid (TFA) in water (solvent A) and acetonitrile (ACN, solvent B) . The flow was 20 mL min À1 .Al inear gradient was applied with an increase from 10 to 100 %Bwithin 20 min. b-Carbolines were further purified by semipreparative HPLC using an Agilent 1200 instrument equipped with aZ orbax Eclipse XDB-C 18 column (250 9.4 mm, 5 mm). and the same solvents, applying af low of 2mLmin À1 and al inear gradient from 10 to 100 %Bw ithin 10 min. The final purification was accomplished with the same solvents and instrument, but using a Phenomenex Synergi RP-80 column (250 10 mm, 4 mm) and agradient that included an initial hold at 30 %Bfor 1min, an increase to 65 %Bwithin 10 min, and to 100 %Bwithin further 30 sec. This procedure yielded 3.5 mg of 4 and 14.4 mg of 5,w hich were dissolved in [D 6 ]DMSO for subsequent NMR analysis (below).
HPLC and mass spectrometry
HPLC and mass spectrometry were performed on aT hermo Accela liquid chromatograph equipped with aC 18 column (Grom-Sil 100 ODS-0 AB, 250 4.6 mm, 3 mm) fitted to an Exactive Orbitrap spectrometer,u sing electrospray ionization. The respective diode array detectors covered the wavelength range of l = 200-400 nm. Initially,H PLC-UV chromatograms were extracted at l = 280 nm (to detect 1), later at l = 300 nm to detect b-carbolines. Conditions for HPLC included solvents 0.1 %T FA in water (A) and 0.1 %T FA in ACN (B) at af low rate of 0.4 mL min À1 .T he gradient was:i nitial hold at 10 %Bfor 1min, and linear increase to 98 %Bwithin 4min. Standard analytical runs were performed on aT hermo Vanquish Horizon UHPLC system equipped with ad iode array and af luorescence detector.T his instrument was equipped with aP henomenex Kinetex XB-C 18 column (100 2.1 mm, 1.7 mmparticle size). For fluorescence detection, excitation and emission were at l = 340 and 410 nm, respectively.S olvents were 0.1 %f ormic acid (FA) in water (A) and ACN (B) at af low rate of 1mLmin À1 .T he gradient was:i nitial hold at 5% Bf or 1min, and linear increase to 100 %Bwithin 15 min. Chromatography and mass spectrometry to quantify the concentration of 4 was done on an Agilent 1290 Infinity II UHPLC instrument with ad iode array detector (DAD) and interfaced to a 6130 quadrupole mass detector,r un in ESI mode. The chromatograph was equipped with aP henomenex Luna Omega Polar C 18 50 2.1 mm (1.6 mmp article size) and ag uard column. Separation was at 25 8Ca nd af low of 0.5 mL min À1 .M obile phase Aw as 0.1 % aqueous FA,p hase Bw as ACN+ +0.1 %F A. Al inear gradient was applied (% B): initially 1%,w ithin 3min to 10 %, and within further 1min to 100 %. UV/Vis spectra were recorded with the diode-array detector during LC-MS analyses. Samples were dissolved in MeOH.
MALDI-MS imaging
P. cubensis mycelium was directly grown on indium tin oxide (ITO)coated glass slides for Imaging MS. ITO glass slides were placed inside petri dishes and covered with 20 mL of MEP agar to form a thin layer on which cultures were grown at room temperature for up to 4d.S ubsequently,t he slides were dried overnight at 37 8C and sprayed with 2.5 mL of universal MALDI matrix (1:1 mixture of 2,5-dihydroxybenzoic acid and a-cyano-4-hydroxycinnamic acid) dissolved at 20 mg mL À1 in am ixture of acetonitrile, methanol and water (70:25:5), using the automatic ImagePrep device 2.0 (Bruker Daltonics) with 60 consecutive cycles (a 1808 rotation of the sample after 30 cycles was performed) of 31 seconds (1 ss praying, 10 si ncubation time, and 20 so fa ctive drying). Samples were then analyzed on an UltrafleXtreme MALDI TOF/TOF instrument (Bruker Daltonics), operated in the positive reflector mode using flexControl 3.0. The analysis was performed from 100 Da to 3,000 Da, accumulating 500 shots by taking 10 random shots at each raster position (raster width 200 mm). The acquisition method was externally calibrated using the Peptide Calibration Standard II (Bruker Daltonics). Spectra were processed with baseline subtraction in flexAnalysis 3.3. Images were obtained using root mean square normalization and brightness optimization.
Nuclearmagneticr esonance spectroscopy
NMR spectra were recorded on aB ruker AvanceI II 600 MHz spectrometer at 300 K. The solvent was [D 6 ]DMSO .
1 Ha nd 13 CNMR chemical shifts were referenced relative to residual protons present in deuterated DMSO at d H = 2.49 ppm and d C = 39.5 ppm.
Syntheses of reference compounds
To synthesize 6,w ef ollowed the protocol by Snyder et al. [23] but substituted ethyl acetate by formaldehyde. The synthesis of 7 was carried out as described. [18] For 8 synthesis, ap ublished procedure was applied, [24] but replacing HBr by HCl. Am ixture of 9 and 10 was synthesized following apublished procedure. [25] 
